Cochrane · systematic review · CD012867
Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
Jung, JH, McCutcheon, KAnn, Borofsky, M, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
17
No studies
1
Included studies
NR
No studies 1 · 5.6%Ungraded 0 · 0%Very low 5 · 27.8%Low 8 · 44.4%Moderate 4 · 22.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsPAE compared to TURP for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (short term)
Population: men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scoresa PAE vs TURP | no estimate extracted | 6 studies · 360 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of lifea PAE vs TURP | no estimate extracted | 5 studies · 300 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Major adverse events PAE vs TURP | RR 0.75 [0.19, 2.97] | 4 studies · 250 participants | Very low Downgraded: risk of bias, imprecision |
Retreatmenta PAE vs TURP | RR 3.2 [1.41, 7.27] | 4 studies · 303 participants | Moderate Downgraded: risk of bias |
Erectile functiona PAE vs TURP | no estimate extracted | 2 studies · 120 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Ejaculatory disordersh PAE vs TURP | RR 0.51 [0.35, 0.73] | 260 participants | Low Downgraded: risk of bias |
PAE compared to TURP for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (long term)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scores PAE vs TURP | no estimate extracted | 2 studies · 176 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life PAE vs TURP | no estimate extracted | 2 studies · 176 participants | Low Downgraded: risk of bias, imprecision |
Major adverse events PAE vs TURP | RR 0.91 [0.2, 4.05] | 2 studies · 206 participants | Very low Downgraded: risk of bias, imprecision |
Retreatmentf PAE vs TURP | RR 3.8 [1.32, 10.93] | 1 study · 81 participants | Moderate Downgraded: risk of bias |
Erectile function PAE vs TURP | no estimate extracted | 1 study · 81 participants | Low Downgraded: risk of bias, imprecision |
Ejaculatory disorders PAE vs TURP | RR 0.67 [0.45, 0.98] | 1 study · 50 participants | Low Downgraded: risk of bias, imprecision |
PAE compared to sham for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (short term)
Population: men with lower urinary tract symptoms suggesting benign prostatic hyperplasia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Urologic symptom scores PAE vs sham | no estimate extracted | 1 study · 80 participants | Moderate Downgraded: risk of bias |
Quality of life PAE vs sham | no estimate extracted | 1 study · 80 participants | Moderate Downgraded: risk of bias |
Major adverse events PAE vs sham | no estimate extracted | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision |
Retreatment PAE vs sham | no estimate extracted | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision |
Erectile function PAE vs sham | no estimate extracted | NR | No studies |
Ejaculatory disorders PAE vs sham | no estimate extracted | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision |